Date: 2011-04-09
Type of information: Grant
Company: Algipharma (Norway)
Investors: Cystic Fibrosis Foundation Therapeutics (USA)
Amount:
Funding type: grant
Planned used: The grant will be used to perform an in vitro study of Algipharma's proposed cystic fibrosis medicine. The research wil be performed in the United Kingdom.
Others: * On April 9, 2011, AlgiPharma announced that the company has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine. The grant is administered by the Cystic Fibrosis Foundation Therapeutics Inc., a subsidiary of the CFF.
Therapeutic area: Rare diseases - Genetic diseases
